Novel analysis identifies markers that may predict failure of metastatic prostate cancer treatment

New research has identified specific blood-based biomarkers that can predict the failure of prostate cancer treatment in both hormone-sensitive and castration-resistant patients. The study published in The Journal of Molecular Diagnostics identifies platelets, C-reactive protein, and chromogranin A as important indicators in hormone-sensitive prostate cancer patients for the combined androgen deprivation and androgen receptor pathway inhibitor therapy failure to guide alternate treatment.